## CRSP: CRISPR Therapeutics AG - XLV: Healthcare

### Executive Summary

No thesis match: MRS_10 2.2% below STRENGTH zone (3.0-6.0%); PEG unavailable fails VALUE criteria (<1.0). Stock is in no-man's land without clear edge. Caution: momentum weakening (-2.3% MRS).

- **Horizon:** N/A - no position
- **Risk Profile:** N/A - avoiding
- **Stop Type:** Fixed 2xATR ($50.06)
- **If Wrong:** N/A - wait for clearer setup
- **Invalidation:** MRS_10 falling below -5% or breaking key support

### News

- **Articles:** 4
- **Sentiment:** Bullish (Bullish: 1, Bearish: 0)

**1. CRISPR Therapeutics Stock (CRSP) in December 2025: Price, Forecast, CASGEVY Growth and Takeover Rumors**
- Source: ts2.tech | 20251212T130905 | Somewhat-Bullish | Relevance: 100%
- CRISPR Therapeutics (CRSP) in December 2025 is trading around $56, showcasing volatility amid the commercial launch of its gene-editing therapy CASGEVY and promising Phase 1 results for CTX310 for cardiovascular disease. Despite deep Q3 2025 losses, the company maintains a robust cash position of nearly $2 billion, fueling ongoing R&D and pipeline expansion. Takeover rumors are circulating, adding to the stock's unpredictable nature, while Wall Street analysts largely project an upside of 20-35% with significant disagreement due to uncertainties surrounding CASGEVY's commercial scaling and CTX310's long-term potential.

**2. CRISPR Therapeutics AG (NASDAQ:CRSP) Receives Consensus Recommendation of "Hold" from Analysts**
- Source: MarketBeat | 20251213T070941 | Neutral | Relevance: 100%
- CRISPR Therapeutics AG (NASDAQ:CRSP) has received a consensus "Hold" rating from analysts, with an average one-year price target of $67.42. Despite some analysts issuing "buy" ratings and the company beating Q3 EPS estimates, significant insider selling has been noted, including CEO Samarth Kulkarni reducing his stake by 16.68%. Shares opened at $56.68, with a market cap of $5.4 billion, and the company reported Q3 revenue of $0.89 million, missing expectations.

**3. 2 Healthcare Stocks to Buy Ahead of the New Year**
- Source: Finviz | 20251212T180905 | Bullish | Relevance: 100%
- This article highlights CRISPR Therapeutics and Vertex Pharmaceuticals as two excellent healthcare stock candidates for investors looking at long-term growth. CRISPR Therapeutics is expected to see significant pipeline progress, particularly with its gene-editing therapy Casgevy and promising new drug candidates like SRSD107 and CTX112. Vertex Pharmaceuticals, despite market concerns about its dependence on cystic fibrosis treatments, maintains steady revenue and is diversifying its portfolio with new therapies like Journavx and zimislecel.

**4. Is CRISPR Therapeutics (CRSP) Turning Early CTX310 Signals Into a Durable Genetic Medicine Platform?**
- Source: Sahm | 20251210T000941 | Somewhat-Bullish | Relevance: 100%
- CRISPR Therapeutics is gaining attention for its CRISPR-based gene-editing pipeline, particularly with early positive signals from CTX310 for lowering LDL cholesterol and triglycerides. This progress, alongside the commercialization of Casgevy for blood disorders, is reshaping the perception of CRISPR Therapeutics' long-term role in genetic medicine. Despite ongoing financial challenges and dilution risks, the recent Phase 1 success of CTX310 could significantly boost the company's investment narrative and future growth prospects in broad gene-editing treatments.

### Analyst Activity

**Target Signal:** BEARISH (Raises: 0, Lowers: 2)

| Date | Firm | Target | Prior | Change |
|------|------|--------|-------|--------|
| 2025-11-26 | Chardan Capital | $74 | $82 | -10% |
| 2025-11-12 | Citigroup | $77 | $87 | -11% |

**Rating Changes:**

| Date | Firm | Action | Grade |
|------|------|--------|-------|
| 2025-11-26 | Chardan Capital | main | Buy |
| 2025-11-12 | Citigroup | main | Buy |

### Insider Activity (90 days)

| Metric | Value |
|--------|-------|
| Direction | **NET_SELLING** |
| Buys | 5 ($0.00M) |
| Sells | 6 ($3.81M) |

### Institutional Ownership

| Metric | Value |
|--------|-------|
| Total Ownership | 45.9% |
| Smart Money | **BULLISH** |
| Net Flow | 0.0% |
| Buying/Selling | 5 / 5 |

**Top Holders:**
- ARK Investment Manag: 10.3% (-3.9%)
- Blackrock Inc.: 7.4% (+16.2%)
- Capital Internationa: 5.9% (+1.0%)
- Orbis Allan Gray Ltd: 5.2% (+80.2%)
- State Street Corpora: 4.2% (+22.5%)

### Key Risks

1. Insider selling cluster: $3.8M in recent transactions.
2. High short interest (26.4%, 8.9 days to cover): squeeze risk or crowded bearish bet.
3. Near-term weakness: 6.5% below SMA50 despite long-term uptrend.

### Catalysts

- Broader market risk-on sentiment could lift quality names.
- Year-end positioning and window dressing may support price.

### Fundamentals

Balance sheet: strong liquidity (16.2x), low leverage (D/E 0.17). Revenue growth strong at 1916% YoY. Analyst sentiment negative (2 target cuts vs 0 raises). Insider selling cluster ($3.8M in 90 days), potential headwind. Institutional flow bullish (5 buying vs 5 selling).

| Metric | Value |
|--------|-------|
| Market Cap | $5.4B |
| Beta | 1.73 |
| 52W Range | $30.04 - $78.48 |
| Short Interest | 26.4% |

| Valuation | Value |
|-----------|-------|
| PEG Ratio | -0.21 |
| Forward P/E | N/A |
| Current P/E | N/A |
| YoY Growth | N/A |
| EPS Direction | None |

### Technicals

MRS_10 deteriorating from 4.5% to 2.2% (-2.3% in 5 days), indicating relative weakness vs NASDAQ. Below STRENGTH zone by 0.8pp (needs >3.0% for momentum thesis). MRS_5 at 0.2% confirms short-term momentum alignment. MACD histogram positive (0.88), confirming momentum. RSI neutral at 51. OFD pattern: -SLL (Support test).

| Metric | Value | Signal |
|--------|-------|--------|
| MRS_10 | 2.18% (CS: 54) | Neutral |
| RSI_14 | 50.8 | Neutral |
| MACD Histogram | 0.88 | Bullish |
| vs SMA20 | 1.045x | Above |
| vs SMA50 | 0.935x | Below |
| vs SMA200 | 1.116x | Above |

### Decision

- **Verdict:** AVOID
- **Thesis:** NEUTRAL

### Trade Setup

- **Entry:** $56.68
- **Stop Loss:** $50.06 (11.7% risk)
- **Target:** $63.30 (R:R method)
- **Risk/Reward:** 1.00:1
- **Target Reasoning:** NEUTRAL thesis targets 1.0x risk/reward based on historical edge

### Position Sizing

- **Shares:** 151
- **Position Value:** $8,558.68
- **Portfolio %:** 8.56%
- **Risk Dollars:** $1,000.00
- **Risk Per Trade:** 1.00%
- **Modifiers:** L1 100% | L2 100% | Combined 1.00x

### Market Context

| Layer | Signal | Modifier |
|-------|--------|----------|
| L1 Macro | NORMAL (MEDIUM) | 1.00x |
| L2 Sector | NEUTRAL (Zone E) | 1.00x |

*NORMAL regime with moderate risk appetite ahead of Fed decision. VIX remains calm at 15.74 while breadth shows modest participation at 54%, suggesting selective positioning. FOMC meeting in 4 days creates near-term uncertainty but no systemic stress evident.*

### Earnings

**Next:** 2026-02-18 (Est: $-1.23)

| Quarter | Est | Actual | Surprise |
|---------|-----|--------|----------|
| 2025Q3 | $-1.29 | $-1.17 | +9.2% |
| 2025Q2 | $-1.40 | $-1.29 | +7.8% |
| 2025Q1 | $-1.28 | $-1.58 | -23.8% |
| 2024Q4 | $-1.19 | $-0.44 | +62.9% |

---
*RULE-based L3 | 2026-01-06 16:37 | MRS_10*